Last reviewed · How we verify
DORZOLAMIDE HYDROCHLORIDE
At a glance
| Generic name | DORZOLAMIDE HYDROCHLORIDE |
|---|---|
| Modality | Small molecule |
| Phase | FDA-approved |
| First approval | 1994 |
Approved indications
Common side effects
- Taste perversion (bitter, sour, or unusual taste)
- Ocular burning and/or stinging
- Conjunctival hyperemia
- Blurred vision
- Superficial punctate keratitis
- Eye itching
- Abdominal pain
- Back pain
- Blepharitis
- Bronchitis
- Cloudy vision
- Conjunctival discharge
Serious adverse events
- Cardiac arrest
- Pulmonary edema
- Cerebral ischemia
- Anaphylaxis
- Angioedema
- Bronchospasm
- Systemic lupus erythematosus
- Myasthenia gravis exacerbation
- Retroperitoneal fibrosis
- Cystoid macular edema
Key clinical trials
- Efficacy and Safety of HUC3-637 in Patients With Primary Open Angle Glaucoma or Ocular Hypertension (PHASE3)
- Retinal Ganglion Cell Neuroprotection Under Prostaglandin Analogues
- Stop Retinal Ganglion Cell Dysfunction Study (PHASE3)
- Efficacy of Simbrinza and Rocklatan vs Cosopt and Latanoprost (PHASE4)
- PRO-122 Versus Concomitant Therapy in Subjects With Uncontrolled Primary Open-angle Glaucoma (PRO-122LATAM) (PHASE3)
- Dorzolamide+Timolol Multidose Preservative-free vs Dorzolamida+Timolol BAK Preserved Efficacy and Safety (PHASE4)
- How Much Does Reduced Dosing of Latanoprost and Dorzolamide-timolol Affect Pressure? (PHASE4)
- Impact of Timolol/Dorzolamide Therapy on Autoregulation in Glaucoma Patients (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| FDA label | Mechanism, indications, dosing, boxed warnings, drug interactions |
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- DORZOLAMIDE HYDROCHLORIDE CI brief — competitive landscape report
- DORZOLAMIDE HYDROCHLORIDE updates RSS · CI watch RSS